VIA
ATRA icon

Vident Investment Advisory’s Atara Biotherapeutics ATRA Stock Holding History

Vident Investment Advisory’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,994
Closed -$695K – 1280
2022
Q1 		$695K Buy
2,994
+492
+20% +$157K 0.02% 822
2021
Q4 		$986K Sell
2,502
-1,552
-38% -$653K 0.03% 712
2021
Q3 		$1.81M Sell
4,054
-290
-7% -$104K 0.05% 472
2021
Q2 		$1.69M Buy
4,344
+1,634
+60% +$583K 0.05% 474
2021
Q1 		$973K Sell
2,710
-14
-0.5% -$6.19K 0.03% 616
2020
Q4 		$1.34M Buy
+2,724
New +$1.26M 0.05% 449
2020
Q2 		– Sell
-3,662
Closed -$779K – 841
2020
Q1 		$779K Sell
3,662
-229
-6% -$72.7K 0.05% 464
2019
Q4 		$1.6M Buy
3,891
+1,328
+52% +$458K 0.1% 317
2019
Q3 		$905K Sell
2,563
-73
-3% -$27.2K 0.08% 188
2019
Q2 		$1.32M Buy
2,636
+1,186
+82% +$837K 0.11% 134
2019
Q1 		$1.44M Sell
1,450
-38
-3% -$35.3K 0.08% 355
2018
Q4 		$1.29M Sell
1,488
-572
-28% -$531K 0.07% 364
2018
Q3 		$2.13M Sell
2,060
-137
-6% -$134K 0.08% 312
2018
Q2 		$2.02M Sell
2,197
-2,515
-53% -$2.7M 0.08% 324
2018
Q1 		$4.56M Buy
4,712
+1,280
+37% +$1.17M 0.19% 77
2017
Q4 		$1.55M Sell
3,432
-305
-8% -$113K 0.07% 310
2017
Q3 		$1.55M Buy
3,737
+113
+3% +$42.6K 0.08% 309
2017
Q2 		$1.27M Buy
3,624
+1,397
+63% +$538K 0.11% 298
2017
Q1 		$1.14M Buy
2,227
+371
+20% +$154K 0.11% 295
2016
Q4 		$659K Buy
1,856
+547
+42% +$232K 0.08% 321
2016
Q3 		$700K Sell
1,309
-6
-0.5% -$3.26K 0.09% 316
2016
Q2 		$740K Sell
1,315
-372
-22% -$179K 0.1% 303
2016
Q1 		$802K Buy
1,687
+787
+87% +$354K 0.05% 358
2015
Q4 		$594K Buy
+900
New +$681K 0.08% 351

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vident Investment Advisory's ATRA Position: Q2 2022 in Review

Vident Investment Advisory sold out of Atara Biotherapeutics (ATRA) in Q2 2022, closing a stake of 2,994 shares — an estimated $695K sold.

Vident Investment Advisory first reported a position in ATRA in Q4 2015 and held it in 24 quarters. The position peaked at $4.56M in Q1 2018. 134 funds tracked by Wall St. Rank hold ATRA as of Q2 2022.

  • Vident Investment Advisory reported no remaining Atara Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 2,994 Atara Biotherapeutics shares in Q2 2022, an estimated $695K.
  • Vident Investment Advisory first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 24 quarters.
  • Vident Investment Advisory's Atara Biotherapeutics position peaked at $4.56M in Q1 2018.
  • 134 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2022.

Based on Vident Investment Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.